An inhalation solution for early treatment and prevention
SoftOx is developing a novel, self-administered inhaled drug for early treatment and prevention of influenza-like illnesses. The pan-virucidal effects of SoftOx Inhalation Solution (SIS) circumvents the need for expensive diagnostic procedures and potential delays to treatment. Due to its non-specific mechanism of virus killing and inactivation, SoftOx Inhalation Solution has the potential to be an ideal “go to” intervention for new emergent viruses.
How it works
SIS is an aqueous, isotonic formulation of hypochlorous acid, stabilised for aerosolisation and suitable for administration to the respiratory tract (e.g., using a standard nebuliser). SoftOx hypothesizes that SIS inactivates and kills intracellular and extracellular virus in the upper and lower respiratory tract, resulting in a reduction in viral load, thereby improving symptoms, shortening disease duration, and preventing onward disease transmission. Such a drug would be ideal in the efforts to limit the health and societal impact of SARS-CoV-2 and future pandemics.